The JAVELIN Head & Neck 100 trial is the first of its kind to open in Ireland. It increases treatment opportunities for some Irish patients.
It is a Phase III double-blind randomised controlled trial (RCT) studying the effect of avelumab, versus placebo, in combination with standard of care CRT in the frontline treatment of patients with high risk locally advanced squamous cell carcinoma of the head and neck (SCCHN).
The trial has opened in St Luke’s Radiation Oncology Network in Rathgar and St James’s Hospital, Dublin. It is funded by Pfizer and with the support of St Luke’s Institute of Cancer Research and Cancer Trials Ireland.